An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis.
An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis.
复制标题
DOI：
10.1016/j.vaccine.2009.08.096
复制
发表时间：
2009-11
期刊：
影响因子：
5.5
通讯作者：
Qilong Wang;Qin Pan;Yunfeng Ma;Kun Wang;P. Sun;Shengwu Liu;Xiao-lian Zhang
中科院分区：
文献类型：
--
作者：
Qilong Wang;Qin Pan;Yunfeng Ma;Kun Wang;P. Sun;Shengwu Liu;Xiao-lian Zhang
有必要开发针对结核病(TB)的保护性疫苗，以引起包括粘膜免疫在内的全面免疫反应。为此，我们研制了携带结核分枝杆菌H37Rv ESAT6-Ag85B融合基因的猪伤寒沙门氏菌SL7207载体活疫苗SL(E6-85B)。实验数据表明，SL(E6-85B)疫苗或与卡介苗联合接种时，可诱导出最强的TB Ag特异性粘膜、体液和细胞免疫应答，包括T细胞增殖、干扰素-γ表达、颗粒酶B的产生，以及效应者记忆T(TEM)或效应者CD8+T细胞应答的最大干扰素-γ的产生，与其他免疫组(仅用SL(Ag85B)、DNA疫苗或卡介苗免疫的小鼠)相比，该疫苗对结核分枝杆菌H37Rv强毒攻击具有较高的保护效力。这一策略可能代表着一种新的、有希望的预防结核病的粘膜疫苗候选方案，这种疫苗生产成本低、有效，并且能够口服而不是注射。
There is a need to develop protective vaccines against tuberculosis (TB) that elicit full immune responses including mucosal immunity. Here, a live attenuated Salmonellatyphimurium aroA SL7207 vector TB vaccine, namely SL(E6-85B), harboring the Mycobacterium tuberculosis (M. tb) H37Rv ESAT6-Ag85B fusion gene was developed. The experimental data demonstrated that this SL(E6-85B) vaccine, or when it is combined with BCG vaccination, induced the strongest TB Ag-specific mucosal, humoral, and cellular immune responses comprised of increased proliferation of T cells, IFN-gamma expression, granzyme B production, as well as the greatest IFN-gamma production of effector-memory T (TEM) or effector CD8+T cell responses and exerted high protective efficacy in mice against virulent M. tb H37Rv challenge compared to the other vaccinated groups (mice immunized with SL(Ag85B), a DNA vaccine or BCG only). This strategy may represent a novel promising mucosal vaccine candidate for the prevention of TB which are inexpensive to produce, efficacious, and able to be given orally rather than by injection.